Dainippon Of Japan Begins Final Trials Of Enhanced Schizophrenia Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma is beginning the second of three Phase III trials of its schizophrenia drug it says has survived all tests so far. The drug's active pharmaceutical ingredient is lurasidone, intended to be a competitor of Eli Lilly's Zyprexa (olanzapine) and AstraZeneca's Seroquel (quetiapine). The final two Phase III trials are intended to test lurasidone against those two drugs, with a target of completing the trials by year-end and submitting applications to U.S. FDA next year. In addition to test the drug against the two big sellers, Dainippon also is testing its efficacy for improving cognitive functions. (Click here for more - a subscription may be required
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.